• View patient site
  • Order
Oncimmune
  • Our Company
    • About Oncimmune
    • Board of Directors
    • Scientific Board
    • Regulation & Quality
    • Press Releases
    • Events & News
  • Products
    • Lung Cancer Blood Test
    • Liver Cancer Blood Test
  • Resources
    • Industry Publications
    • Oncimmune Resources
    • Videos
  • Investors
    • Corporate Governance
    • Regulatory Newsflow
    • Share Price and Tools
    • Shareholder Analysis
    • Analyst Coverage
    • Results, Reports & Presentations
    • Corporate Documents
    • Investor & Advisor Contacts
    • Aim Rule 26
  • Contact Us
  • Our Company
    • About Oncimmune
    • Board of Directors
    • Scientific Board
    • Regulation & Quality
    • Press Releases
    • Events & News
  • Products
    • Lung Cancer Blood Test
    • Liver Cancer Blood Test
  • Resources
    • Industry Publications
    • Oncimmune Resources
    • Videos
  • Investors
    • Corporate Governance
    • Regulatory Newsflow
    • Share Price and Tools
    • Shareholder Analysis
    • Analyst Coverage
    • Results, Reports & Presentations
    • Corporate Documents
    • Investor & Advisor Contacts
    • Aim Rule 26
  • Contact Us

Early Cancer Detection Insights

Back to All Posts
Share on Facebook Share on LinkedIn Share on Twitter Share on Google+ Send Email

Oncimmune (USA) Experiences Increased Interest in EarlyCDT®—Lung as Doctors Place New Emphasis on Lung Cancer Screening with CT, in Response to Landmark NLST Study

By Kuno Creative | December 21, 2011

Previous Post All Posts Next Post

Popular Posts

  • World Lung Cancer Day: Promoting Lung Cancer Awareness
  • Oncimmune USA LLC Receives 2016 Best of DeSoto Award
  • A Warm Welcome to Dr James Jett
  • Study Validates the Cost-Effectiveness of EarlyCDT-Lung
  • UK Lung Cancer Survival Rate Should And Can Be Better….
  • Is Scotland sitting on a Cancer Time bomb?
  • Positive Early Lung Cancer Study Results Announced
oncimmune
brand

Oncimmune Holdings Plc
Clinical Sciences Building,
Nottingham City Hospital
Hucknall Road, Nottingham,
NG5 1PB, United Kingdom
+44 (0)115 82 31869

 

Registered in England and Wales number 09818395

Oncimmune (USA) LLC
8960 Commerce Drive,
Building #6,
De Soto,
KS 66018, USA
1 913 583 9000
1 888 583 9030

Terms & Conditions Privacy Policy Cookies
twitter facebook linkedin